🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 670.79 +0.3% NASDAQ 100: 603.31 +0.5% Dow Jones: 470.90 +0.1%

Steven Cohen’s HBIO Holdings & Trades

First Buy
Q4 2025
Duration Held
1 Quarters
Largest Add
Q4 2025
+14,717 Shares
Current Position
1,472 Shares
$9,843 Value

Steven Cohen's HBIO Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1,472 shares of Harvard Bioscience, Inc. (HBIO) worth $9,843, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Steven Cohen has initiated a new position in HBIO, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Harvard Bioscience (HBIO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Harvard Bioscience (HBIO) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +14,717 New Buy 1,472 $6.69

Steven Cohen's Harvard Bioscience Investment FAQs

Steven Cohen first purchased Harvard Bioscience, Inc. (HBIO) in Q4 2025, acquiring 1,472 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Harvard Bioscience, Inc. (HBIO) for 1 quarters since Q4 2025.

Steven Cohen's largest addition to Harvard Bioscience, Inc. (HBIO) was in Q4 2025, adding 1,472 shares worth $9,843.

According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,472 shares of Harvard Bioscience, Inc. (HBIO), valued at approximately $9,843.

As of the Q4 2025 filing, Harvard Bioscience, Inc. (HBIO) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Harvard Bioscience, Inc. (HBIO) was 1,472 shares, as reported at the end of Q4 2025.